Back to search results

Active Surveillance for Papillary Thyroid Microcarcinoma

This study is looking at an approach called active surveillance for papillary thyroid microcarcinoma (PTMC), a type of thyroid cancer. Instead of immediate surgery, which is the usual treatment, active surveillance means doctors will carefully watch the cancer to see if it grows or spreads. The goal is to understand how often PTMC progresses when it's watched closely over 3, 5, and 10 years. You might be able to join if you have a thyroid nodule 2.0 cm or smaller that is highly suspected to be or confirmed as papillary thyroid carcinoma, or if you have certain genetic markers (BRAF mutation). This study aims to enroll 216 participants.

Study design
This is an interventional study, meaning participants will receive a specific intervention (active surveillance). It plans to enroll 216 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 10 years from the time of diagnosis to measure disease progression.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02609685

Active Surveillance of Papillary Thyroid Microcarcinoma

Recruiting
NAAges 18+Interventional
Cedars-Sinai Medical Center
~216 participants
Updated 2026-05-07 on ClinicalTrials.gov
What's tested:Active Surveillance

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of disease progression
Measured over From time of diagnosis up to10 years of follow-up

Conditions

Papillary Thyroid Microcarcinoma

Explore related trials

Thyroid Gland CarcinomaThyroid Gland Papillary MicrocarcinomaBRAF Gene

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Allen Ho, MD · PRINCIPAL_INVESTIGATOR · Cedars-Sinal Medical Center

Who to contact

Allen Ho, MD
[email protected]
310-423-1220
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pathologically confirmed Bethesda V or VI thyroid nodules with papillary thyroid carcinoma or high clinical suspicion, or pathologically confirmed Bethesda III or IV nodules with BRAF mutation.
2.0 cm or smaller nodules by ultrasonographic criteria
Ability to understand and the willingness to sign a written informed consent and HIPAA Authorization form
Must be able to read and write English fluently to participate in the questionnaire portion of the study

Exclusion

High-grade or poorly differentiated PTC variants
Central or lateral neck lymphadenopathy suspicious for PTC
Unfavorable nodule location (e.g. Near dorsal surface (by recurrent laryngeal nerve); Adjacent to trachea (risk of cartilage invasion)
History of radiation to neck

What this trial measures

  • Rate of disease progressionFrom time of diagnosis up to10 years of follow-up